The Bull Case For Incyte (INCY) Could Change Following New Minjuvi And Zynyz Approvals In Europe And Japan [Yahoo! Finance]
Incyte Corporation (INCY)
Last incyte corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
incyte.com/ir/investor-overview.aspx
Company Research
Source: Yahoo! Finance
Zynyz (retifanlimab) in new combination regimens for relapsed or refractory follicular lymphoma and advanced squamous cell carcinoma of the anal canal, expanding treatment options across major oncology markets. These approvals meaningfully broaden Incyte's oncology footprint in Europe and Japan while deepening its presence in chemotherapy-free and first-line cancer care. Next, we'll examine how Minjuvi's expanded European and Japanese indications could reshape Incyte's investment narrative and future growth mix. Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit To own Incyte, you generally need to believe that its expanding oncology portfolio can gradually rebalance dependence on Jakafi while funding further R&D. The Minjuvi and Zynyz approvals in Europe and Japan support that diversification effort, but do not change that the key near term catalyst remains execution on new product launches, and the biggest
Show less
Read more
Impact Snapshot
Event Time:
INCY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INCY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INCY alerts
High impacting Incyte Corporation news events
Weekly update
A roundup of the hottest topics
INCY
News
- Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer [Yahoo! Finance]Yahoo! Finance
- Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular LymphomaBusiness Wire
- Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal CancerBusiness Wire
- Incyte (INCY): Revisiting Valuation After a Strong Year-to-Date Share Price Rally [Yahoo! Finance]Yahoo! Finance
- Incyte to Present at Upcoming Investor ConferenceBusiness Wire
INCY
Earnings
- 10/28/25 - Beat
INCY
Sec Filings
- 12/22/25 - Form 4
- 12/19/25 - Form 144
- 12/19/25 - Form 144
- INCY's page on the SEC website